RBL-001

About Rebel Medicine

Rebel Medicine is a private, preclinical-stage biotechnology company developing novel, extended-release local anesthetics to address the opioid crisis in post-operative pain management. The company's core technology platform enables the formulation of bupivacaine into long-acting gels and solutions, with its lead asset, Alevatrix™, having completed a Pre-IND meeting. Backed by non-dilutive grant funding from the NSF and NIH, Rebel aims to establish a new standard of care in loco-regional anesthesia that minimizes or eliminates the need for systemic opioids after surgery.

Therapeutic Areas